Objective: To assess effectiveness of intravitreous bevacizumab in a cohort of patients with neovascular age-related macular degeneration (nAMD) in British Columbia, Canada.
Design: Retrospective cohort study.
Participants: Patients with new-onset AMD who completed 1 year of bevacizumab treatment.